Table 2 Characteristics and resistance profiles of presumptive MDR-TB patients, MDR-TB surveillance programme, Madagascar, 2012–2017

Total

20

268

488

469

536

610

2391

 Male

12 (60.0)

195 (73.3)

326 (66.9)

302 (65.4)

359 (67.0)

426 (70.0)

1620 (68.1)

 Female

8 (40.0)

71 (26.7)

161 (33.1)

160 (34.6)

177 (33.0)

183 (30.0)

760 (31.9)

Median age (in years ± SD)

45 ± 16.4

40 ± 13.2

40 ± 13.3

39 ± 14.4

40 ± 14.2

41 ± 14.7

40 ± 14.1

 Relapse

4 (20.0)

107 (39.9)

257 (52.7)

302 (64.4)

376 (70.2)

430 (70.5)

1476 (61.7)

 Failure

8 (40.0)

69 (25.8)

82 (16.8)

58 (12.4)

43 (8.0)

73 (12.0)

333 (13.9)

 Retreatment

0 (0.0)

21 (7.8)

53 (10.9)

54 (11.5)

54 (10.1)

61 (10.0)

243 (10.2)

 Unknown

8 (40.0)

71 (26.5)

96 (19.7)

55 (11.7)

63 (11.8)

46 (7.5)

339 (14.2)

 Pulmonary

20 (100.0)

249 (93.6)

482 (98.8)

452 (96.6)

526 (98.1)

580 (95.2)

2309 (96.7)

 Extrapulmonary

0 (0.0)

17 (6.4)

6 (1.2)

16 (3.4)

10 (1.9)

29 (4.8)

78 (3.3)

 MTBC

16 (84.2)

229 (85.5)

440 (90.2)

367 (78.6)

438 (81.7)

478 (78.4)

1968 (82.4)

 Non-MTBC

3 (15.8)

39 (14.5)

48 (9.8)

100 (21.4)

98 (18.3)

132 (21.6)

420 (17.6)

 Pan-susceptible

9 (56.3)

199 (86.9)

392 (89.1)

331 (90.2)

368 (84.0)

427 (89.3)

1726 (87.7)

 Isoniazid monoresistance

3 (18.8)

11 (4.8)

24 (5.5)

14 (3.8)

38 (8.7)

23 (4.8)

113 (5.7)

 Rifampicin monoresistance

0 (0.0)

3 (1.3)

6 (1.4)

4 (1.1)

7 (1.6)

6 (1.3)

26 (1.3)

 MDR-TB

3 (18.8)

13 (5.7)

17 (3.9)

16 (4.4)

19 (4.3)

21 (4.4)

89 (4.5)

 Pre-XDR-TB

0 (0.0)

1 (0.4)

1 (0.2)

1 (0.3)

0 (0.0)

0 (0.0)

3 (0.2)

 XDR-TB

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Other¹

1 (0.1)

2 (0.1)

0 (0.0)

1 (0.1)

6 (0.3)

1 (0.1)

11 (0.5)